Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 17, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas to Present Initial Data from Ongoing Clinical Trials and a Pipeline Update at the 2nd Targeted Protein Degradation Summit

Platform Presentation to Include Initial Safety, Tolerability, and Pharmacokinetic Data from Ongoing Phase 1 TrialsNeuroscience Presentation to Include Data from Preclinical Tau and Alpha-Synuclein...
October 02, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Strengthens Scientific Advisory Board with Leaders in Oncology and Neurological Disorders

NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that six new...
October 01, 2019 04:00 ET | Source: Arvinas Inc.

Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio

- Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields- John Dombrosky Announced as CEO of Oerth Bio - Transaction had been formally...
August 27, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of ARV-471, an Estrogen Receptor-Targeting PROTAC® Protein Degrader

NEW HAVEN, Conn., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the...
August 07, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas To Present at the Wedbush PacGrow Healthcare Conference

NEW HAVEN, Conn. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that...
August 05, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today reported...
July 29, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer

NEW HAVEN, Conn., July 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today the...
July 25, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk

NEW HAVEN, Conn., July 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced today that...
July 18, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference

NEW HAVEN, Conn., July 18, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will...
June 25, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer

- Initiation of Phase 1 Trial expected in the third quarter of 2019 - ARV-471 will be Arvinas’ second targeted PROTAC® protein degrader to enter the clinic NEW HAVEN, Conn., June 25, 2019 ...